Allogene Therapeutics Inc (NAS:ALLO)
$ 2.14 -0.05 (-2.28%) Market Cap: 459.18 Mil Enterprise Value: 269.53 Mil PE Ratio: 0 PB Ratio: 0.99 GF Score: 37/100

Allogene Therapeutics Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript

Sep 14, 2020 / 07:00PM GMT
Release Date Price: $35.35 (+9.17%)
Vikram Purohit
Morgan Stanley, Research Division - Equity Analyst

Okay. Great. Well, welcome, everybody, to the Allogene Therapeutics fireside chat. I am Vikram Purohit. I'm one of the Morgan Stanley biotech analysts. And before we get started, I have to read a brief disclosure.

So please note that this webcast is for Morgan Stanley's clients and appropriate Morgan Stanley employees only. This webcast is not for members of the press. If you are a member of the press, please disconnect and reach out separately. For important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. And if you have any questions, please reach out to your Morgan Stanley sales representative. With that, I would like to welcome Eric Schmidt, CFO of Allogene. Eric, welcome.

Eric Thomas Schmidt;Vikram Purohit<
Allogene Therapeutics, Inc. - CFO

Thank you very much, Vikram. Thank you, Morgan Stanley for hosting.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot